Prothena Corporation reported second quarter 2026 financial results on August 6, 2026. The company posted a net loss of $18.6 million for the quarter and net income of $14.1 million for the first six months, compared to losses in the prior year period. Total revenue was $1.0 million in Q2 and $52.1 million for the first half, driven by a $50.0 million milestone payment from Novo Nordisk and collaboration revenue from Bristol Myers Squibb. Cash and restricted cash stood at $289.1 million as of June 30, 2026. The company updated its full-year 2026 cash guidance to approximately $259 million, reflecting share repurchases. Prothena is a late-stage clinical biotechnology company focused on developing therapeutics for neurodegenerative and amyloid diseases.